The competition between brand name and generic pharmaceutical companies is fierce. Although the Hatch Waxman Act attempted a compromise between the opposing positions of Branded pharmaceuticals and Generics, ANDA litigation and, increasingly, settlements, continue to be a major component of strategy and development on both sides. The webcast's panel stakes out these competing positions.
Topics covered include:
- Limitations on Settlement of Brand and Generic litigation
- Relationship of Authorized Generics to Settlement of brand-generic litigation
- At-risk launches in brand-generic litigation
Former Senior VP Chief IP Counsel, Allergan, Inc.
Partner at Fitzpatrick Cella
Former Senior VP Global IP to Ranbaxy Labs
Partner at Goodwin Procter
Partner at Kenyon & Kenyon LLP
Edward W. Murray
Managing Counsel, Intellectual Property Litigation Merck & Co., Inc.